Financial Data and Key Metrics Changes - The company reported total revenue of $22,500,000 for Q1 2025, a 24% increase from $18,100,000 in Q1 2024, driven by strong growth in the RNS business [7][15] - Gross margin improved to 77% in Q1 2025 from 73.6% in Q1 2024, primarily due to increased manufacturing efficiency [16] - Net loss decreased to $6,600,000 in Q1 2025 from $8,900,000 in Q1 2024, indicating improved operational performance [18] Business Line Data and Key Metrics Changes - RNS sales increased by 26% year-over-year, and by 29% when excluding Nautilus study implants from Q1 2024 [8][15] - Sales of Dixie Medical SEEG products also contributed to revenue growth during the quarter [15] Market Data and Key Metrics Changes - The company expects a compound annual growth rate (CAGR) of over 20% through 2027, driven by RNS opportunities [14] - The company anticipates minimal revenue impact from the termination of SEEG product distribution in 2025, as remaining inventory will be sold during the transition [13] Company Strategy and Development Direction - The company is focusing on expanding access to RNS therapy, with key initiatives including Project CARE and a refocused product portfolio [8][12] - The company aims to establish the RNS system as the standard of care for drug-resistant epilepsy patients [12] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the growth trajectory, citing strong adoption of RNS therapy and ongoing clinical development initiatives [9][14] - The company plans to achieve cash flow breakeven by the end of 2027, supported by a strengthened balance sheet following a recent equity raise [18][19] Other Important Information - The company completed a $75,000,000 follow-on equity financing, enhancing its shareholder base [8] - The company is working on expanding indications for pediatric focal epilepsy and has had discussions with the FDA regarding data from the Pediatric Epilepsy Research Consortium [11] Q&A Session Summary Question: Inquiry about gross margin performance - Management confirmed that the strong gross margin of 77% was primarily driven by the RNS business and increased production volumes [24][25][26] Question: Impact of Project CARE on referral volumes - Management noted that Project CARE has positively impacted referral volumes and implants, with increasing referrals from level three and community centers [33][35] Question: Hiring cadence throughout the year - Management indicated consistent investment in the commercial organization to support growth opportunities in core centers and new geographies [36][39] Question: Challenges in training doctors in community settings - Management stated that while support is required for new centers, the organization is experienced in training and supporting new prescribers [44][46] Question: Feedback from physicians on post-approval study data - Management reported positive feedback from physicians regarding the compelling data presented, which is expected to drive engagement and sales [57][60] Question: Exit from Dixie Medical and its implications - Management acknowledged the loss of visibility in the diagnostic process but emphasized the importance of leveraging existing relationships to maintain patient care quality [78][82]

Financial Data and Key Metrics Changes - Total revenue for the first quarter of 2025 was $22,500,000, representing a 24% increase compared to $18,100,000 in the prior year period [5][12] - RNS sales increased by 26%, or 29% when excluding the impact of Nautilus study implants in Q1 2024 [6][12] - Gross margin for the first quarter of 2025 was 77%, up from 73.6% in the same period of 2024 [13] - Net loss for the first quarter of 2025 was $6,600,000, compared to $8,900,000 in the first quarter of 2024 [15] Business Line Data and Key Metrics Changes - RNS system sales were the primary driver of revenue growth, with a 26% increase year-over-year [12][13] - Sales of Dixie Medical SEEG products also contributed to growth, although specific figures were not detailed [12] Market Data and Key Metrics Changes - The company expects a 20% plus compound annual growth rate (CAGR) through 2027, indicating strong market potential for RNS therapy [11] - The company anticipates minimal revenue impact from the termination of SEEG product distribution in 2025, as remaining inventory will be sold during the transition period [11] Company Strategy and Development Direction - The company is focusing on expanding access to RNS therapy, with a record number of prescribers and ongoing momentum from Project CARE [6][10] - Strategic initiatives include a focus on clinical, product, and market development, with plans to establish the RNS system as the standard of care for drug-resistant epilepsy [6][10] - The company is transitioning away from SEEG products to concentrate on higher-margin RNS business opportunities [10] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the growth trajectory, citing strong execution and strategic initiatives that are expected to drive future performance [12][18] - The company is on track to achieve cash flow breakeven by the end of 2027, supported by a strengthened balance sheet following a recent equity raise [15][11] Other Important Information - The company completed a $75,000,000 follow-on equity financing, enhancing its shareholder base [6][12] - The gross margin for RNS products was particularly strong due to improved manufacturing efficiency [13] Q&A Session Summary Question: Inquiry about gross margin and Dixie revenue - Management confirmed that the strong gross margin was primarily driven by the RNS business, with negligible Dixie revenue impacting the overall margin [20][21] Question: Impact of Project CARE on referral volumes - Management noted increasing referral volumes into level four centers, contributing to growth, and emphasized the importance of Project CARE in expanding access to RNS therapy [28][30] Question: Hiring cadence and personnel investments - Management indicated a consistent approach to hiring, focusing on building the commercial organization to capitalize on growth opportunities [32][34] Question: Difficulty in training doctors for RNS procedures - Management stated that while support is required for new centers, the organization is experienced in training and supporting clinicians [39][41] Question: Feedback from physicians on post-approval study data - Management reported positive feedback from physicians regarding the compelling data presented, which is expected to enhance engagement and sales efforts [51][56] Question: Exit from Dixie and maintaining visibility - Management acknowledged the loss of some visibility but emphasized leveraging existing relationships and knowledge gained from the Dixie partnership [72][75]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For transition period from to Commission File Number 001-40337 NEUROPACE, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organi ...

This presentation may contain forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as "aims," "anticipates," "believes," "could," "estimates," "expects," "forecasts," "goal," "intends," "may," "plans," "possible," "potential," "seeks," "will" and variations of these words or similar expressions that are intended to identify forward-looking statements, although not all forward-looking s ...

Financial Performance - Reported record quarterly revenue of $22.5 million in Q1 2025, a 24% increase from $18.1 million in Q1 2024[5] - RNS System revenue grew 26% year-over-year in Q1 2025, or 29% when excluding revenue from implants in the NAUTILUS study in Q1 2024[6] - Increased full-year 2025 revenue guidance to $93 million - $97 million, representing growth of 16% - 21% compared to $79.9 million in 2024[13] - Gross margin for Q1 2025 was 77.0%, exceeding the full-year guidance range of 73% - 75%[7] Operating Expenses and Losses - Operating expenses increased by 8% year-over-year to $22.5 million in Q1 2025, driven by R&D investments[8] - Loss from operations improved to $5.1 million in Q1 2025, compared to $7.5 million in the prior year[9] - Net loss for Q1 2025 was $6.6 million, down from $8.9 million in Q1 2024[9] Cash Position - Cash, cash equivalents, and short-term investments totaled $66.3 million as of March 31, 2025, up from $52.8 million at the end of the prior quarter[9] Strategic Focus - The company is on track to announce topline data from the NAUTILUS pivotal study in the second half of 2025[2] - Strategic refocusing on the core RNS System product line, with plans to wind down the distribution relationship for SEEG products by Q1 2026[6]

-- Reported record quarterly revenue of $22.5 million in Q1 2025, driven by increasing market demand for core RNS System products -- -- Increased full-year 2025 revenue guidance to $93 to $97 million -- -- On track to announce topline data from the NAUTILUS pivotal study in the second half of 2025 -- -- Management scheduled to host a conference call today at 4:30 p.m. ET -- MOUNTAIN VIEW, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transformin ...

Core Viewpoint - The article emphasizes the importance of identifying and maintaining trends in short-term investing, highlighting that sound fundamentals and positive earnings estimates are crucial for sustaining momentum in stocks [1]. Group 1: Stock Screening and Selection - The "Recent Price Strength" screen is a unique short-term trading strategy that helps identify stocks with strong fundamentals capable of maintaining an uptrend [2]. - NeuroPace, Inc. (NPCE) is highlighted as a suitable candidate that has shown a solid price increase of 8.6% over the past 12 weeks, indicating investor confidence [3]. - NPCE has experienced a significant price increase of 25.3% over the last four weeks, suggesting that the upward trend is still intact [4]. Group 2: Fundamental Analysis - NPCE is currently ranked 2 (Buy) by Zacks Rank, placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate revisions and EPS surprises [5]. - The Zacks Rank system has a strong track record, with Zacks Rank 1 stocks averaging an annual return of +25% since 1988, indicating the effectiveness of this ranking system [6]. - The Average Broker Recommendation for NPCE is 1 (Strong Buy), reflecting high optimism from the brokerage community regarding its near-term price performance [6]. Group 3: Investment Strategy - The article suggests that NPCE's price trend is unlikely to reverse soon, and encourages investors to explore other stocks that meet the criteria of the "Recent Price Strength" screen [7]. - The Zacks Research Wizard is mentioned as a tool for backtesting stock-picking strategies, which can help investors identify profitable opportunities based on historical performance [8].

-- Minimal expected impact to operations and financial results -- -- Company to report first quarter 2025 financial results on May 13, 2025 -- MOUNTAIN VIEW, Calif., April 14, 2025 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today provided an update on its exposure to tariffs that have been implemented. While specific policies and timing of implementation remain fluid, NeuroPace expects minimal impact to its o ...

Three-year data from the largest FDA-reviewed prospective neuromodulation study of safety and effectiveness in drug-resistant focal epilepsy1Long-term seizure reduction with a median reduction of 82% at 3 years.Seizure freedom with 42% of patients remaining seizure free for 6+ months.i MOUNTAIN VIEW, Calif., April 08, 2025 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced three-year effectiveness dat ...

MOUNTAIN VIEW, Calif., April 03, 2025 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (NASDAQ:NPCE), a medical device company focused on transforming the lives of people living with epilepsy, will be attending and presenting at the upcoming American Academy of Neurology (AAN) 2025 Annual Meeting, which is being held in San Diego from April 5 – 9. This includes an oral presentation on data from the Post-Approval Study (PAS) of the RNS® System in adults treated with brain-responsive stimulation for drug-resistant focal e ...